16 reports of this reaction
1.6% of all PHENAZOPYRIDINE HYDROCHLORIDE reports
#14 most reported adverse reaction
DYSURIA is the #14 most commonly reported adverse reaction for PHENAZOPYRIDINE HYDROCHLORIDE, manufactured by i-Health, Inc.. There are 16 FDA adverse event reports linking PHENAZOPYRIDINE HYDROCHLORIDE to DYSURIA. This represents approximately 1.6% of all 1,029 adverse event reports for this drug.
Patients taking PHENAZOPYRIDINE HYDROCHLORIDE who experience dysuria should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSURIA is a less commonly reported adverse event for PHENAZOPYRIDINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dysuria, the following adverse reactions have been reported for PHENAZOPYRIDINE HYDROCHLORIDE:
The following drugs have also been linked to dysuria in FDA adverse event reports:
DYSURIA has been reported as an adverse event in 16 FDA reports for PHENAZOPYRIDINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSURIA accounts for approximately 1.6% of all adverse event reports for PHENAZOPYRIDINE HYDROCHLORIDE, making it a notable side effect.
If you experience dysuria while taking PHENAZOPYRIDINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.